About
TearSolutions develops Lacripep, a proprietary topical peptide therapy derived from the tear protein Lacritin, intended to treat ocular surface diseases like dry eye by restoring tear film stability and improving corneal health.
Explore TearSolutions's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.